A multinational research team has developed a three-drug combination that may effectively inhibit enterovirus replication in human cell and organoid cultures. The combination demonstrated effectiveness without detectable cytotoxicity and delayed the emergence of antiviral drug resistance. It has the potential for treating enterovirus-triggered type 1 diabetes and maintaining cardiac function. The combination's safety profiles in humans may accelerate its pathway to clinical use against enterovirus infections.

Source: Cellular and Molecular Life Sciences